



eye-light®

Our leading dual-therapy platform
in a completely overhauled experience.

Smarter. Scalable.
Designed around your practice needs.



Today, eye-light®
evolves even further.

eye-light® is Espansione Group's flagship light-based device for comprehensive ophthalmic care, combining **LM™ LLLT Photobiomodulation (PBM)** and **OPE™ IPL** technologies to deliver **non-invasive, evidence-based treatments** for **anterior segment conditions**.


Introducing a new modular
software architecture.



Not all solutions and use cases available in all countries. Every piece of information shown ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.

The all-new eye-light®. Built around your practice.

The latest evolution of eye-light® introduces a **modular, software-driven treatment architecture**, developed to adapt seamlessly to different clinical specialties, organizational models and stages of each practice' growth journey.




Modular treatment protocols activation.

Treatments are no longer limited to fixed configurations.

↳ **Fully modular eye-light®** — Access **up to eight treatment protocols** for anterior segment conditions.

↳ **Activate new protocols anytime** — As practice needs evolve, unlock new protocols **without changing the device** and elevate your practice.



Smarter guidance. Consistent treatments.

The new software introduces advanced operational intelligence, supporting clinicians and staff during every step of the treatment workflow.

↳ Real-time **system checks** to ensure correct device configuration.

↳ **Smart alerts** to prevent improper use.

↳ **On-screen guidance** to support correct treatment setup.



Next-Generation Hardware & Software.

↳ **Responsive & Intuitive** — A new, powerful CPU coupled with a state-of-the-art 7" touchscreen ensures fast, smooth system interaction.

↳ **Stable & Reliable** — The new **Linux-based OS** delivers seamless performance for a consistent user experience.



Results

- | | | |
|---|--|--|
| ① | Increased operational consistency. | Standardized workflows, real-time system checks and guided setup ensure each treatment is performed according to predefined parameters, regardless of operator or setting. |
| ② | Reduced variability between operators. | On-screen guidance, smart alerts and automated checks minimize subjective interpretation, reducing operator-dependent variability during treatment setup and delivery. |
| ③ | Optimized treatment outcomes. | Consistent execution, reduced variability and protocol-driven guidance contribute to more controlled treatment delivery, supporting outcome optimization over time. |



LM™ LLLT and OPE™ IPL: a dual-technology ecosystem.

*Available only for Anterior Segment use.

LM™ LLLT is our **patented photobiomodulation (PBM)** technology using **three light wavelengths**, each tailored to specific cellular responses and clinical needs.

■ LM™ LLLT RED

- > Increasing ATP production
- > Reducing inflammation through ROS modulation
- > Protecting cells from hypoxia via regulation of IF-1 α

■ LM™ LLLT BLUE

- > Reducing bacterial load
- > Inducing bacterial cell death
- > Promoting microbiome stabilization

■ LM™ LLLT YELLOW

- > Modulating vasodilatation in hypoxia condition via NO release
- > Improving oxygenation
- > Reducing oxidative stress

OPE™ IPL* is our **patented Intense Pulsed Light** technology, **software-controlled** to deliver calibrated thermal impulses for optimal safety and efficacy.

OPE™ IPL

- > Improves blood circulation
- > Enhances anti-inflammatory cytokines secretion

Applications



Anterior Segment

The multi-wavelength, **dual light therapy** approach allows eye-light® to be leveraged in the management of a wide array of **ocular surface conditions** (e.g., DED/MGD, Chalazion, CLD, Sjögren's Syndrome, Blepharitis, Demodex, Rosacea) and in the elevation of **surgical outcomes** (e.g., cataract, refractive) via tear film stabilization.



Not all solutions and use cases available in all countries. Every piece of information shown ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.

Scientific Coverage

Anterior Segment



TFOS DEWS III Management and Therapy Report

JONES, Lyndon J. et al.
American Journal of Ophthalmology,
2025.

“ **LM™ LLLT is recognized by TFOS DEWS III as a management tool for DED and OSD that:**

- > Stimulates cellular metabolism through PBM
- > Reduces inflammation and improves lipid secretion
- > Enhances patient comfort and tear film quality

“ **Cataract surgery often induces or worsens dry eye, compromising visual quality and patient satisfaction.**

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery: A Prospective Randomized Double-Masked Controlled Clinical Trial

TIMOFTE-ZORILA, Mihaela M. et al.
Ophthalmology & Therapy, 2025.

Parameter	Group	T0	T1	T3	p value*
OSDI	LLLT	26.62 ± 15.42	15.53 ± 12.04	13.36 ± 11.69	< 0.001
	Control	20.80 ± 12.67	22.32 ± 14.86	25.50 ± 14.26	0.033
	p value†	0.055	0.02	< 0.001	
BUT (s)	LLLT	5.76 ± 3.99	6.69 ± 4.48	8.38 ± 4.53	0.002
	Control	7.14 ± 3.65	6.45 ± 4.15	7.14 ± 4.08	0.416
	p value†	0.092	0.799	0.179	
Tear osmolarity (mOsm/l)	LLLT	300.69 ± 14.19	-	296.11 ± 12.30	0.048
	Control	296.66 ± 15.64	-	306.20 ± 14.59	0.002
	p value†	0.206	-	< 0.001	

> Prophylactic LLLT significantly improved Ocular Surface Disease Index (OSDI) scores and tear-film stability in patients with cataracts.

> LLLT was effective in preventing postoperative increases in tear osmolarity and ocular surface damage.

LEGEND


- PBM
- SHAM

Outcomes of LLLT for the prophylaxis of Iatrogenic Dry Eye after Cataract Surgery: A Prospective Randomized Double-Masked Controlled Clinical Trial


GIANNACCARE, Giuseppe et al.
British Journal of Ophthalmology,
May 2023.

Results

OSDI > LOW IS BETTER



NIBUT > HIGHER IS BETTER



Protocols

PBM

7 ± 2 days
preop

7 ± 2 days
postop

30 ± 4 days
postop

SHAM

7 ± 2 days
preop

7 ± 2 days
postop

30 ± 4 days
postop



Not all solutions and use cases available in all countries. Every piece of information shown ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.



Find out more.

espansionegroup.it/solutions/eye-light/

Discover
eye-light®

Click here to visit our **Scientific Community**
espansionegroup.it/scientific-community/

**JOIN US AT THE FOREFRONT
INNOVATION.**